Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ADC, mainly ADC<sub>oscillating</sub> , increased in the group of nodules with intermediate malignancy (ADC<sub>pulsed</sub> : 0.75 ± 0.25 × 10<sup>-3</sup> mm<sup>2</sup> /s vs. 0.64 ± 0.07 × 10<sup>-3</sup> mm<sup>2</sup> /s in benign nodules, P = 0.025; ADC<sub>oscillating</sub> : 0.81 ± 0.20 × 10<sup>-3</sup> mm<sup>2</sup> /s vs. 0.65 ± 0.13 × 10<sup>-3</sup> mm<sup>2</sup> /s, P = 0.0008) and ADC<sub>pulsed</sub> decreased in the group of progressed hepatocellular carcinomas (ADC<sub>pulsed</sub> : 0.60 ± 0.08 × 10<sup>-3</sup> mm<sup>2</sup> /s, P = 0.042; ADC<sub>oscillating</sub> : 0.68 ± 0.08 × 10<sup>-3</sup> mm<sup>2</sup> /s, P = 0.1).
|
31507025 |
2020 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In univariate analysis, lower ADC, axial diffusivity, and radial diffusivity were associated with malignancy (OR = 0.37-0.42 per 1-SD increase, p < 0.001 for each), as was higher FA (OR = 1.45, p = 0.007).
|
31484577 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To determine if PSAD, PSADtz, and ADC values improve the accuracy of PI-RADS v2 and identify men whose concurrent systematic biopsy detects clinically significant cancer on areas without mpMRI visible lesions.
|
31136112 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, statistically significant differences were found between the noncancer and cancer groups in T2 values and ADC values (diff TEs) (P = 0.000).
|
31218387 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Background</b>: MicroRNAs (miRNAs) are becoming recognized as novel diagnostic and prognostic biomarkers in several malignancies, including non-small-cell lung cancer (NSCLC). miR-25 is overexpressed in small cell lung cancer (SCLC) and NSCLC tissues, and high miR-25 expression is associated with poorer overall survival of women with lung ADC.
|
30919763 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DW MRI is a promising non-invasive MRI technique used to differentiate recurrent/residual head and neck malignancies from posttreatment changes based on ADC values.
|
31422219 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ADC products based on the non-internalizing 1959 antibody may be useful for the treatment of several human malignancies, as the cognate antigen is abundantly expressed and secreted by several cancers, while being present at low levels in most normal adult tissues.
|
30553852 |
2019 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There are no previous reports on the impact of AZIN2 expression in human cancer.
|
30768610 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The 10th percentile ADC obtained from ultrahigh b-value DWI performed better for differentiating TZ cancer from BPH.
|
30475249 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that in future studies of PI-RADSv2 upgraded category 4 and category 4 based on markedly low ADC value should be reported separately to generate a database for meta-analysis of cancer rates.
|
29362152 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We performed a logistic regression analysis to examine each institute's weighting of T2w, ADC and K<sup>trans</sup> intensity maps in the delineation of the cancer.
|
29731160 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The estimate of Ln probability of malignancy (low, moderate, high) was based on nodal size, border contour and signal intensity and comparison between ADC value of the Ln's belonging to the three different classifications were performed.
|
28497665 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, over-representation of cancer-stimulating α7-nAChR in SQC-L, also potentiated by smoking, and under-representation of cancer-inhibiting α4β2-nAChR in ADC-L could explain the different tobacco influences on the tumorigenic process in each cancer type.
|
28978081 |
2017 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The payload was successfully conjugated to trastuzumab and the resulting ADC exhibited potent activity against a HER2-expressing human cancer cell line in vitro.
|
28188066 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This suggests that the cytotoxicity and immunosuppressive capacity of A7R-ADC could be modulated to treat specific malignancies or autoimmune diseases through the introduction of different payloads, and represents a novel alternative to steroid therapy.
|
28878234 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ADC<sub>min</sub> was measured, by two independent, blinded readers, using a region of interest (ROI) of 5-10 mm<sup>2</sup> at the area of lowest ADC value within a cancer, while ADC<sub>mean</sub> was measured using an ROI covering more than half of a cancer.
|
26823024 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
For transition zone, significantly increased cancer detection was shown for location (anterior 0.63±0.15 vs. mid/posterior 0.31±0.14; p=0.0048), border (pseudo-capsule 0.32±0.14 vs. ill-defined 0.61±0.15; p=0.0092), and ADC (mild 0.35±0.12 vs marked restriction 0.68±0.17; p=0.0057).
|
28987685 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
At multivariable analysis of entropy in combination with all other ADC histogram and conventional MRI features, entropy was the only significant independent predictor of malignancy (p = 0.004).
|
27900458 |
2017 |